Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
Association between EGFR T790M status and progression patterns during initial EGFR-TKI treatment in patients harboring EGFR mutation
Y Oya, T Yoshida, H Kuroda, J Shimizu, Y Horio… - Clinical lung cancer, 2017 - Elsevier
Background Emergence of the T790M point mutation in exon 20 of the epidermal growth
factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine …
factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine …
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
The study was to compare the effectiveness of different epidermal growth factor receptor—
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
D Chen, Z Song, G Cheng - OncoTargets and therapy, 2016 - Taylor & Francis
Purpose Subsets of non-small-cell lung cancer patients with epidermal growth factor
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI …
T Yoshida, H Kuroda, Y Oya, J Shimizu, Y Horio… - Lung Cancer, 2017 - Elsevier
Background Emergence of the T790M point mutation in exon 20 of epidermal growth factor
receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase …
receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase …
[HTML][HTML] T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
C Ma, S Wei, Y Song - Journal of thoracic disease, 2011 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
相关搜索
- cell lung cancer patients
- egfr mutations clinical outcomes
- egfr mutations lung cancer
- t790m mutation status
- japanese patients gefitinib erlotinib
- clinical efficacy gefitinib erlotinib
- egfr mutation progression patterns
- clinical efficacy egfr tkis
- retrospective comparison gefitinib erlotinib
- egfr tki acquired resistance
- egfr exon 20 mutations
- japanese patients retrospective comparison
- clinical efficacy retrospective comparison
- clinical efficacy japanese patients
- egfr tki clinical outcomes
- egfr tkis lung cancer